A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma.
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 05 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
- 06 Jan 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 03 May 2014 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.